

# A Novel One Step Real Time RT-PCR Assay for the Detection of Enterovirus



An enterprise of the University of Utah and its Department of Pathology

Weston C. Hymas<sup>1</sup> and David R. Hillyard<sup>1,2</sup>

Institute for Clinical and Experimental Pathology<sup>1</sup>, Department of Pathology<sup>2</sup>, University of Utah Health Sciences Center, Salt Lake City, Utah.

## Introduction

Enteroviruses (EV) are the leading cause of aseptic meningitis in pediatric and adult populations and can be associated with severe disease such as myocarditis, encephalitis, and paralytic poliomyelitis. RT-PCR has rapidly become the diagnostic methodology of choice due to its sensitivity and rapid turn-around-time allowing significant improvement in patient care and management. Most molecular assays target the highly conserved regions within the 5' nontranslated region (NTR) described by Rotbart et al. We describe the development of a novel real time assay that amplifies and detects a conserved region upstream of the Rotbart amplicon utilizing primers and an Eclipse probe. As a further enhancement, an RNA internal control (IC) is integrated into the reaction. The analytical sensitivity was determined and a comparison to the Chemicon Oligodetect Pan-enterovirus kit was made during the 2005 enterovirus season.

## Results

Analytical sensitivity was determined using 2-fold serial dilutions of positive control material. The real time assay demonstrated 100% analytical sensitivity compared to the PCR-Chemicon assay (Figure 1 & Table 2).

Twenty-two of the 76 specimens were positive for enterovirus using the PCR-ELISA method, whereas the real-time assay identified only 16 out of these 22. The remaining 54 specimens were negative by both assays (Table 3).

DNA sequencing was performed on the 6 discrepant patient specimens that failed to exhibit a recognizable crossing threshold in the real time assay. Sequencing results indicated the upstream priming region in 5 of the 6 discrepant samples contained one variable nucleotide position with two distinct single nucleotide polymorphisms (SNP). Four discrepant samples contained a T to G SNP. One of the remaining two samples contained a T to A polymorphisms (Figure 2). These SNPs appear to be newly discovered during this study.

## Conclusion

This real time assay design containing an RNA internal control demonstrated excellent analytical sensitivity when compared to the PCR-ELISA assay. However, upon testing individual and unique clinical samples it became evident that the clinical sensitivity was substandard due to unidentified polymorphisms underneath a primer. Although the frequency of these SNPs in nature is uncertain, the identification of 6 out of 22 (27%) positive patient specimens in this study suggests that this region may be potentially compromised in a considerable percentage of enterovirus specimens. This discovery lends a warning to all groups using or developing new assays for enterovirus that there may be additional unknown SNPs within the "conserved" 5' NTR and that these tests should be rigorously validated using clinical samples. Future directions for this assay include incorporating modified bases to accommodate the newly described SNPs.

Primers and probes	Sequence	Nucleotide positions <sup>a</sup>
--------------------	----------	-----------------------------------

### PCR-ELISA

EV1	5' - CCTCCGGCCCCCTGAATGCGGCTAAT - 3'	449-473
EV2	5' - biotin-ATTGTCACCATAAGCAGCCA - 3'	583-602
Probe (Antisense)	5' - GAAACACGGACACCCAAAGTA - 3'	547-567

### Real time RT-PCR Assay

EV-F	5' - GA*AGAGA*CTAG*TGA*GCTA - 3'	422-439
EV-R	5' - GTTAGGA*TTAGCCGCATTC - 3'	461-479
Probe	5' - MGB - TCCGGCCCCCTGAATGC - FAM - 3'	451-466

IC - Forward	5' - CCA*TCAA*GTCGA*GGTGCCTAAAGTG - 3'	1513-1538 <sup>b</sup>
IC - Reverse	5' - ACGAACGCCATGCGGCTACAGGAAGCTC - 3'	1563-1590
IC Probe	5' - MGB - TGTGGTGGTGTAGAGC - PY - 3'	1550-1566

<sup>a</sup>Corresponding nucleotide position in Cox B5

<sup>b</sup>Corresponding nucleotide position in ms2 Phage

A\*, G\* = super A base, super G Nanogen/Epoch Biosciences

Table 1. Primers and probes used for the detection of Enterovirus from patient specimens by the 2 assays.




Figure 1. Amplification of 2-fold serial dilutions of positive control material.

Dilution	Real Time C <sub>T</sub>	Chemicon OD
1	38.47	> 3.0
2	38.85	2.465
3	39.30	1.353
4	41.57	0.615
5	43.78	0.394
6	44.68	Neg
7	46.74	Neg
8	Neg	Neg

Table 2. Analytical sensitivity comparison between the 2 assays using serial 2-fold dilutions of control material.

	Chemicon +	Chemicon -
Real Time +	16	0
Real Time -	6	54

Table 3. Comparative results of the 76 samples tested in both assays.

```
Cox A 2  GGTCCGAAGAGCCTATTGAGCTAGTTAGTAGTCTCCGGCCCCCTGAATGGCGCTAATCTAACTTCGGGAGCAATGCGCTCAAACCGAGGGGTGGTGTGTGTAACCGTAACTTCGCAAGGGAAACCGGACTACTTTGGGTTCCTCGGTGTTTCCTTTATTCTTATAATGGGTGCTATGGTGACAATTA
Cox A 3  GGTCCGAAGAGCCTATTGAGCTAGTTAGTAGTCTCCGGCCCCCTGAATGGCGCTAATCTAACTTCGGGAGCAATGCGCTCAAACCGAGGGGTGGTGTGTGTAACCGTAACTTCGCAAGGGAAACCGGACTACTTTGGGTTCCTCGGTGTTTCCTTTAAATTTTACTGGTGTGCTATGGTGACAATTA
Cox A 4  GGTCCGAAGAGCCTATTGAGCTAGTTAGTAGTCTCCGGCCCCCTGAATGGCGCTAATCTAACTTCGGGAGCAATGCGCTCAAACCGAGGGGTGGTGTGTGTAACCGTAACTTCGCAAGGGAAACCGGACTACTTTGGGTTCCTCGGTGTTTCCTTTATTCTTATGTTGGTGTGCTATGGTGACAATTA
Cox A 5  GGTCCGAAGAGCCTATTGAGCTAGTTAGTAGTCTCCGGCCCCCTGAATGGCGCTAATCTAACTTCGGGAGCAATGCGCTCAAACCGAGGGGTGGTGTGTGTAACCGTAACTTCGCAAGGGAAACCGGACTACTTTGGGTTCCTCGGTGTTTCCTTTATTCTTATAATGGGTGCTATGGTGACAATTA
Cox A 6  GGTCCGAAGAGCCTATTGAGCTAGTTAGTAGTCTCCGGCCCCCTGAATGGCGCTAATCTAACTTCGGGAGCAATGCGCTCAAACCGAGGGGTGGTGTGTGTAACCGTAACTTCGCAAGGGAAACCGGACTACTTTGGGTTCCTCGGTGTTTCCTTTATTCTTATAATGGGTGCTATGGTGACAATTA
Cox A 7  GGTCCGAAGAGCCTATTGAGCTAGTTAGTAGTCTCCGGCCCCCTGAATGGCGCTAATCTAACTTCGGGAGCAATGCGCTCAAACCGAGGGGTGGTGTGTGTAACCGTAACTTCGCAAGGGAAACCGGACTACTTTGGGTTCCTCGGTGTTTCCTTTATTCTTATAATGGGTGCTATGGTGACAATTA
Cox A 8  GGTCCGAAGAGCCTATTGAGCTAGTTAGTAGTCTCCGGCCCCCTGAATGGCGCTAATCTAACTTCGGGAGCAATGCGCTCAAACCGAGGGGTGGTGTGTGTAACCGTAACTTCGCAAGGGAAACCGGACTACTTTGGGTTCCTCGGTGTTTCCTTTATTCTTATAATGGGTGCTATGGTGACAATTA
Cox A 9  GGTCCGAAGAGCCTATTGAGCTAGTTAGTAGTCTCCGGCCCCCTGAATGGCGCTAATCTAACTTCGGGAGCAATGCGCTCAAACCGAGGGGTGGTGTGTGTAACCGTAACTTCGCAAGGGAAACCGGACTACTTTGGGTTCCTCGGTGTTTCCTTTATTCTTATAATGGGTGCTATGGTGACAATTA
Cox A 10 GGTCCGAAGAGCCTATTGAGCTAGTTAGTAGTCTCCGGCCCCCTGAATGGCGCTAATCTAACTTCGGGAGCAATGCGCTCAAACCGAGGGGTGGTGTGTGTAACCGTAACTTCGCAAGGGAAACCGGACTACTTTGGGTTCCTCGGTGTTTCCTTTATTCTTATAATGGGTGCTATGGTGACAATTA
Cox A 12 GGTCCGAAGAGCCTATTGAGCTAGTTAGTAGTCTCCGGCCCCCTGAATGGCGCTAATCTAACTTCGGGAGCAATGCGCTCAAACCGAGGGGTGGTGTGTGTAACCGTAACTTCGCAAGGGAAACCGGACTACTTTGGGTTCCTCGGTGTTTCCTTTATTCTTATAATGGGTGCTATGGTGACAATTA
Cox A 13 GGTCCGAAGAGCCTATTGAGCTAGTTAGTAGTCTCCGGCCCCCTGAATGGCGCTAATCTAACTTCGGGAGCAATGCGCTCAAACCGAGGGGTGGTGTGTGTAACCGTAACTTCGCAAGGGAAACCGGACTACTTTGGGTTCCTCGGTGTTTCCTTTATTCTTATAATGGGTGCTATGGTGACAATTA
Cox A 14 GGTCCGAAGAGCCTATTGAGCTAGTTAGTAGTCTCCGGCCCCCTGAATGGCGCTAATCTAACTTCGGGAGCAATGCGCTCAAACCGAGGGGTGGTGTGTGTAACCGTAACTTCGCAAGGGAAACCGGACTACTTTGGGTTCCTCGGTGTTTCCTTTATTCTTATAATGGGTGCTATGGTGACAATTA
Cox A 15 GGTCCGAAGAGCCTATTGAGCTAGTTAGTAGTCTCCGGCCCCCTGAATGGCGCTAATCTAACTTCGGGAGCAATGCGCTCAAACCGAGGGGTGGTGTGTGTAACCGTAACTTCGCAAGGGAAACCGGACTACTTTGGGTTCCTCGGTGTTTCCTTTATTCTTATAATGGGTGCTATGGTGACAATTA
Cox A 16 GGTCCGAAGAGCCTATTGAGCTAGTTAGTAGTCTCCGGCCCCCTGAATGGCGCTAATCTAACTTCGGGAGCAATGCGCTCAAACCGAGGGGTGGTGTGTGTAACCGTAACTTCGCAAGGGAAACCGGACTACTTTGGGTTCCTCGGTGTTTCCTTTATTCTTATAATGGGTGCTATGGTGACAATTA
Cox A 17 GGTCCGAAGAGCCTATTGAGCTAGTTAGTAGTCTCCGGCCCCCTGAATGGCGCTAATCTAACTTCGGGAGCAATGCGCTCAAACCGAGGGGTGGTGTGTGTAACCGTAACTTCGCAAGGGAAACCGGACTACTTTGGGTTCCTCGGTGTTTCCTTTATTCTTATAATGGGTGCTATGGTGACAATTA
Cox A 18 GGTCCGAAGAGCCTATTGAGCTAGTTAGTAGTCTCCGGCCCCCTGAATGGCGCTAATCTAACTTCGGGAGCAATGCGCTCAAACCGAGGGGTGGTGTGTGTAACCGTAACTTCGCAAGGGAAACCGGACTACTTTGGGTTCCTCGGTGTTTCCTTTATTCTTATAATGGGTGCTATGGTGACAATTA
Cox A 20 GGTCCGAAGAGCCTATTGAGCTAGTTAGTAGTCTCCGGCCCCCTGAATGGCGCTAATCTAACTTCGGGAGCAATGCGCTCAAACCGAGGGGTGGTGTGTGTAACCGTAACTTCGCAAGGGAAACCGGACTACTTTGGGTTCCTCGGTGTTTCCTTTATTCTTATAATGGGTGCTATGGTGACAATTA
Cox A 21 GGTCCGAAGAGCCTATTGAGCTAGTTAGTAGTCTCCGGCCCCCTGAATGGCGCTAATCTAACTTCGGGAGCAATGCGCTCAAACCGAGGGGTGGTGTGTGTAACCGTAACTTCGCAAGGGAAACCGGACTACTTTGGGTTCCTCGGTGTTTCCTTTATTCTTATAATGGGTGCTATGGTGACAATTA
Cox A 22 GGTCCGAAGAGCCTATTGAGCTAGTTAGTAGTCTCCGGCCCCCTGAATGGCGCTAATCTAACTTCGGGAGCAATGCGCTCAAACCGAGGGGTGGTGTGTGTAACCGTAACTTCGCAAGGGAAACCGGACTACTTTGGGTTCCTCGGTGTTTCCTTTATTCTTATAATGGGTGCTATGGTGACAATTA
Cox A 24 GGTCCGAAGAGCCTATTGAGCTAGTTAGTAGTCTCCGGCCCCCTGAATGGCGCTAATCTAACTTCGGGAGCAATGCGCTCAAACCGAGGGGTGGTGTGTGTAACCGTAACTTCGCAAGGGAAACCGGACTACTTTGGGTTCCTCGGTGTTTCCTTTATTCTTATAATGGGTGCTATGGTGACAATTA
Cox B 1  GGTCCGAAGAGCCTATTGAGCTAGTTAGTAGTCTCCGGCCCCCTGAATGGCGCTAATCTAACTTCGGGAGCAATGCGCTCAAACCGAGGGGTGGTGTGTGTAACCGTAACTTCGCAAGGGAAACCGGACTACTTTGGGTTCCTCGGTGTTTCCTTTATTCTTATAATGGGTGCTATGGTGACAATTA
Cox B 2  GGTCCGAAGAGCCTATTGAGCTAGTTAGTAGTCTCCGGCCCCCTGAATGGCGCTAATCTAACTTCGGGAGCAATGCGCTCAAACCGAGGGGTGGTGTGTGTAACCGTAACTTCGCAAGGGAAACCGGACTACTTTGGGTTCCTCGGTGTTTCCTTTATTCTTATAATGGGTGCTATGGTGACAATTA
Cox B 3  GGTCCGAAGAGCCTATTGAGCTAGTTAGTAGTCTCCGGCCCCCTGAATGGCGCTAATCTAACTTCGGGAGCAATGCGCTCAAACCGAGGGGTGGTGTGTGTAACCGTAACTTCGCAAGGGAAACCGGACTACTTTGGGTTCCTCGGTGTTTCCTTTATTCTTATAATGGGTGCTATGGTGACAATTA
Cox B 4  GGTCCGAAGAGCCTATTGAGCTAGTTAGTAGTCTCCGGCCCCCTGAATGGCGCTAATCTAACTTCGGGAGCAATGCGCTCAAACCGAGGGGTGGTGTGTGTAACCGTAACTTCGCAAGGGAAACCGGACTACTTTGGGTTCCTCGGTGTTTCCTTTATTCTTATAATGGGTGCTATGGTGACAATTA
Cox B 5  GGTCCGAAGAGCCTATTGAGCTAGTTAGTAGTCTCCGGCCCCCTGAATGGCGCTAATCTAACTTCGGGAGCAATGCGCTCAAACCGAGGGGTGGTGTGTGTAACCGTAACTTCGCAAGGGAAACCGGACTACTTTGGGTTCCTCGGTGTTTCCTTTATTCTTATAATGGGTGCTATGGTGACAATTA
Cox B 6  GGTCCGAAGAGCCTATTGAGCTAGTTAGTAGTCTCCGGCCCCCTGAATGGCGCTAATCTAACTTCGGGAGCAATGCGCTCAAACCGAGGGGTGGTGTGTGTAACCGTAACTTCGCAAGGGAAACCGGACTACTTTGGGTTCCTCGGTGTTTCCTTTATTCTTATAATGGGTGCTATGGTGACAATTA
Echo 1  GGTCCGAAGAGCCTATTGAGCTAGTTAGTAGTCTCCGGCCCCCTGAATGGCGCTAATCTAACTTCGGGAGCAATGCGCTCAAACCGAGGGGTGGTGTGTGTAACCGTAACTTCGCAAGGGAAACCGGACTACTTTGGGTTCCTCGGTGTTTCCTTTATTCTTATAATGGGTGCTATGGTGACAATTA
Echo 2  GGTCCGAAGAGCCTATTGAGCTAGTTAGTAGTCTCCGGCCCCCTGAATGGCGCTAATCTAACTTCGGGAGCAATGCGCTCAAACCGAGGGGTGGTGTGTGTAACCGTAACTTCGCAAGGGAAACCGGACTACTTTGGGTTCCTCGGTGTTTCCTTTATTCTTATAATGGGTGCTATGGTGACAATTA
Echo 3  GGTCCGAAGAGCCTATTGAGCTAGTTAGTAGTCTCCGGCCCCCTGAATGGCGCTAATCTAACTTCGGGAGCAATGCGCTCAAACCGAGGGGTGGTGTGTGTAACCGTAACTTCGCAAGGGAAACCGGACTACTTTGGGTTCCTCGGTGTTTCCTTTATTCTTATAATGGGTGCTATGGTGACAATTA
Echo 4  GGTCCGAAGAGCCTATTGAGCTAGTTAGTAGTCTCCGGCCCCCTGAATGGCGCTAATCTAACTTCGGGAGCAATGCGCTCAAACCGAGGGGTGGTGTGTGTAACCGTAACTTCGCAAGGGAAACCGGACTACTTTGGGTTCCTCGGTGTTTCCTTTATTCTTATAATGGGTGCTATGGTGACAATTA
Echo 5  GGTCCGAAGAGCCTATTGAGCTAGTTAGTAGTCTCCGGCCCCCTGAATGGCGCTAATCTAACTTCGGGAGCAATGCGCTCAAACCGAGGGGTGGTGTGTGTAACCGTAACTTCGCAAGGGAAACCGGACTACTTTGGGTTCCTCGGTGTTTCCTTTATTCTTATAATGGGTGCTATGGTGACAATTA
Echo 6  GGTCCGAAGAGCCTATTGAGCTAGTTAGTAGTCTCCGGCCCCCTGAATGGCGCTAATCTAACTTCGGGAGCAATGCGCTCAAACCGAGGGGTGGTGTGTGTAACCGTAACTTCGCAAGGGAAACCGGACTACTTTGGGTTCCTCGGTGTTTCCTTTATTCTTATAATGGGTGCTATGGTGACAATTA
Echo 7  GGTCCGAAGAGCCTATTGAGCTAGTTAGTAGTCTCCGGCCCCCTGAATGGCGCTAATCTAACTTCGGGAGCAATGCGCTCAAACCGAGGGGTGGTGTGTGTAACCGTAACTTCGCAAGGGAAACCGGACTACTTTGGGTTCCTCGGTGTTTCCTTTATTCTTATAATGGGTGCTATGGTGACAATTA
Echo 9  GGTCCGAAGAGCCTATTGAGCTAGTTAGTAGTCTCCGGCCCCCTGAATGGCGCTAATCTAACTTCGGGAGCAATGCGCTCAAACCGAGGGGTGGTGTGTGTAACCGTAACTTCGCAAGGGAAACCGGACTACTTTGGGTTCCTCGGTGTTTCCTTTATTCTTATAATGGGTGCTATGGTGACAATTA
Echo 11 GGTCCGAAGAGCCTATTGAGCTAGTTAGTAGTCTCCGGCCCCCTGAATGGCGCTAATCTAACTTCGGGAGCAATGCGCTCAAACCGAGGGGTGGTGTGTGTAACCGTAACTTCGCAAGGGAAACCGGACTACTTTGGGTTCCTCGGTGTTTCCTTTATTCTTATAATGGGTGCTATGGTGACAATTA
Echo 25 GGTCCGAAGAGCCTATTGAGCTAGTTAGTAGTCTCCGGCCCCCTGAATGGCGCTAATCTAACTTCGGGAGCAATGCGCTCAAACCGAGGGGTGGTGTGTGTAACCGTAACTTCGCAAGGGAAACCGGACTACTTTGGGTTCCTCGGTGTTTCCTTTATTCTTATAATGGGTGCTATGGTGACAATTA
Enter68 GGTCCGAAGAGCCTATTGAGCTAGTTAGTAGTCTCCGGCCCCCTGAATGGCGCTAATCTAACTTCGGGAGCAATGCGCTCAAACCGAGGGGTGGTGTGTGTAACCGTAACTTCGCAAGGGAAACCGGACTACTTTGGGTTCCTCGGTGTTTCCTTTATTCTTATAATGGGTGCTATGGTGACAATTA
Enter69 GGTCCGAAGAGCCTATTGAGCTAGTTAGTAGTCTCCGGCCCCCTGAATGGCGCTAATCTAACTTCGGGAGCAATGCGCTCAAACCGAGGGGTGGTGTGTGTAACCGTAACTTCGCAAGGGAAACCGGACTACTTTGGGTTCCTCGGTGTTTCCTTTATTCTTATAATGGGTGCTATGGTGACAATTA
Enter70 GGTCCGAAGAGCCTATTGAGCTAGTTAGTAGTCTCCGGCCCCCTGAATGGCGCTAATCTAACTTCGGGAGCAATGCGCTCAAACCGAGGGGTGGTGTGTGTAACCGTAACTTCGCAAGGGAAACCGGACTACTTTGGGTTCCTCGGTGTTTCCTTTATTCTTATAATGGGTGCTATGGTGACAATTA
Enter71 GGTCCGAAGAGCCTATTGAGCTAGTTAGTAGTCTCCGGCCCCCTGAATGGCGCTAATCTAACTTCGGGAGCAATGCGCTCAAACCGAGGGGTGGTGTGTGTAACCGTAACTTCGCAAGGGAAACCGGACTACTTTGGGTTCCTCGGTGTTTCCTTTATTCTTATAATGGGTGCTATGGTGACAATTA
Polio 1 GGTCCGAAGAGCCTATTGAGCTAGTTAGTAGTCTCCGGCCCCCTGAATGGCGCTAATCTAACTTCGGGAGCAATGCGCTCAAACCGAGGGGTGGTGTGTGTAACCGTAACTTCGCAAGGGAAACCGGACTACTTTGGGTTCCTCGGTGTTTCCTTTATTCTTATAATGGGTGCTATGGTGACAATTA
Polio 2 GGTCCGAAGAGCCTATTGAGCTAGTTAGTAGTCTCCGGCCCCCTGAATGGCGCTAATCTAACTTCGGGAGCAATGCGCTCAAACCGAGGGGTGGTGTGTGTAACCGTAACTTCGCAAGGGAAACCGGACTACTTTGGGTTCCTCGGTGTTTCCTTTATTCTTATAATGGGTGCTATGGTGACAATTA
Polio 3 GGTCCGAAGAGCCTATTGAGCTAGTTAGTAGTCTCCGGCCCCCTGAATGGCGCTAATCTAACTTCGGGAGCAATGCGCTCAAACCGAGGGGTGGTGTGTGTAACCGTAACTTCGCAAGGGAAACCGGACTACTTTGGGTTCCTCGGTGTTTCCTTTATTCTTATAATGGGTGCTATGGTGACAATTA
```

```
EV1 CCTCCGGCCCCCTGAATGGCGCTAATCTAACTTCGGGAGCAATGCGCTCAAACCGAGGGGTGGTGTGTGTAACCGTAACTTCGCAAGGGAAACCGGACTACTTTGGGTTCCTCGGTGTTTCCTTTATTCTTATAATGGGTGCTATGGTGACAATTA
EV Probe(ELISA) antisense strand GAAACACGGACACCCAAAGTA
EV2 GGTGTCACCATAAGCAGCCA
EV-F GAAGAGACTAGTGACTA-
Probe TCCGGCCCCCTGAATGC
EV-R CTTAGCCCGATTAGGATTG
```

## Materials and Methods

### Clinical specimens

Seventy-six patient specimens submitted for enterovirus testing at ARUP laboratories were analyzed concurrently with the PCR-ELISA and real time assays. RNA was extracted from 70 µL of each sample using the Qiagen Biorobot 9604. The RNA IC was added to the lysis buffer prior to extraction to yield a final concentration of 300 copies/reaction. All specimens were extracted in duplicate.

### PCR-ELISA

RT-PCR was performed with 20 µL RNA using the OneStep RT-PCR kit and primers and probes listed in Table 1 followed by detection with the Chemicon Pan-Enterovirus Oligodetect kit per the manufacturer's instructions. RT-PCR was performed using the following parameters:

20°C - 10 minutes  
50°C - 30 minutes  
95°C - 15 minutes  
94°C - 15 seconds  
58°C - 30 seconds } 40 Cycles  
72°C - 30 seconds  
72°C - 10 minutes

### Real-time RT-PCR assay

Viral RNA was amplified using the OneStep RT-PCR Kit and primers and probes listed in Table 1. Each 50 µL reaction contained 20 µL of RNA, 120 nM ROX, 1.0 µM each EV primer, and 200 nM of EV probe. The IC primers and probes were at 200 nM and 50 nM respectively. The EV probe contained a 5' minor groove binder and a FAM label on the 3' end, while the IC probe was labeled with PY.

Real time RT-PCR was performed on the Applied Biosystems HT7900 using the following parameters:

20°C - 10 minutes  
50°C - 30 minutes  
95°C - 15 minutes  
95°C - 15 seconds  
56°C - 30 seconds } 50 Cycles  
76°C - 30 seconds  
95°C - 15 seconds  
45°C - 15 seconds } Melt  
95°C - 15 seconds

The final ramp rate of the melt was set at 5%. Data acquisition occurred during the annealing step of each cycle and during the final ramp portion of the melt.



Figure 2. Electropherograms showing newly identified polymorphisms. The uppermost electropherogram is the wild type.

## Research: Pre-Submission Approval Form

Approval is required **before information is presented outside of ARUP and enters the public domain** to ensure that HIPAA and IRB protocols have been followed. Please ensure that this document is signed and appropriate documents are attached before submitting any information for publication/presentation outside of ARUP.

Attach copy of (please indicate) manuscript, poster, abstract, or other presentation

Presentation/Poster presented at (specify meeting or conference): \_\_\_\_\_

ARUP Cited: Yes  No  If no, state reason: \_\_\_\_\_

Global IRB #7275 applies, and PRCS-0020, *Internal Sample Request: De-Identification of Samples* has been followed **OR**

Independent Institutional Review Board (IRB) approval, IRB# \_\_\_\_\_  
Attach copy of approved IRB protocol.

**OR**

IRB is not applicable. Please explain: \_\_\_\_\_

Scientist/Researcher: \_\_\_\_\_ Date: \_\_\_\_\_  
*Signature*

### Approval Signatures and Dates:

Medical Director: \_\_\_\_\_ Date: \_\_\_\_\_

R&D Group Manager or  
ARUP Privacy Officer: \_\_\_\_\_ Date: \_\_\_\_\_

CONFIDENTIAL: This material is prepared pursuant to Utah Code Annotated, 26-25-1, et seq., for the purpose of evaluating health care rendered by hospitals or physicians and it NOT PART of the medical record.